November 16, 2021 7:47am

Time to go fishing, use a high/low rig to bottom fish a mixed-equities catch, that will bounce in your portfolio

Pre-open indications: 3 SELLs, 1 BUY and 1 Pump (or No Promote)

What I provide is an intelligence daily. RMi outlines a daily bell weather of “indications” about what you need to know; it’s what could happen or materialize after the opening and what might happen during the session.

Remember that overnight and pre-open actions in futures doesn't necessarily translate into actual trading in the coming day’s session.


Dow futures are UP +0.16% (+56 points), S&P futures are UP +0.0% (+2 points) and NASDAQ futures are UP +0.01% (+0.50 points)

 

U.S. stock index futures are barely up yet still weak with economic data releases expected

European stocks were incrementally higher

Asia-Pacific stocks were mixed

 

Henry’omics:

Yesterday, the Nasdaq dipped 0.04%, while the Russell 2000 was a relative underperformer, declining 0.45%.

Inflation fears are weighing on the market after last month’s consumer price index posted its largest annual increase in more than three decades. <CNBC>

 

Economic Data Docket: retail sales figures for October; economists expect sales to have jumped by 1.5% last month, compared with 0.7% in September. Industrial production numbers will also be released, as well as the NAHB housing market index survey.

 

If you didn’t remember what happen at Monday night’s close and the quarter’s “number’s” impact, you won’t be prepared for today’s session:

Monday’s evening’s recap: “sector declines - it’s not transitory, infamous current terms. Underlying behavioral element initiate unprecedented downslides, news, an end to earnings cycle and an M&A needed to spur buying” … https://www.regmedinvestors.com/articles/12184

Q4: November, 3 positive and 8 negative close to date

  • October, 8 positive and 13 negative closes

 

Companies in my headlights – It’s your decision; I provide an idea and context:

Maintaining SELL with a Pump or No Promote:

Biostage (BSTG) closed FLAT again at $2.60 with 35 shares traded after Friday’s 0 shares traded, Thursday’s -$0.22 to $2.60 with 2,005 shares traded, Wednesday’s +$0.18 with 2,006 shares traded and last Tuesday’s -$0.03 with 3,304 shares traded

  • Earnings release: Biostage (BSTG) had a net loss of -$800 K, or -$0.80, a $200 K decrease in grant income and a cash position of $2 m—still with NO clinical trial with a 2-year-old IND. Add in some legal negligence ... where its insurance carrier will NOT cover the terminal death suit filed.

What’s there to invest in – the “Sword of Damocles” hanging over its recent insurance company rejection of legal expense/costs of a terminal death suit against the company?

  • For a company with NO clinical trial, an a one (1) and a half year approved IND, four (4) employees and NO CRO <clinical research organization> initiation.

 

Probabilities versus aftermarket/pre-open share pricing indication moves:

BUY:

Regenxbio (RGNX) closed down -$6.07 to $31.72 with a positive +$0.89 or +2.81% pre-open indication.

 

SELL:

Intellia Therapeutics (NTLA) closed up +$1.31 to $133.54 with a negative -$2.94 or -2.20% pre-open indication.

Sage Therapeutics (SAGE) closed down -$1.18 to $41.44 with a negative -$0.89 or -2.15% pre-open indication.

 

SELL into Strength:

Pluristem (PSTI) closed up +$0.12 to $2.93 after Friday’s $2.81 following Thursday’s $2.91, Wednesday’s $2.93 and last Tuesday’s $3.10 with a negative -$0.06 or -2.05% indication.

 

The BOTTOM LINE: As I ask again, “is there a bounce after a trounce and how many?”

I am still manning the bully pulpit, expressing the theme of “Reducing exposure as well as being patient in your willingness to stay fully invested, I’d been recommending very careful buy-ins for the hopes of gains through the month and year-end.

We are seeing to date, two (2) net income – Bellicum Pharmaceuticals (BLCM) and BioLife Solutions (BLFS)

  • Twenty-one (25) net losses to date … Earning’s releases that initiated Q3 reporting season  began the tug-of-war between share pricing that is softer than usual and the usual LPS (loss-per-share) to be less than estimates and expectations.

The stem, cell and gene therapy earnings continue with coming 11/15 (to date with more coming).

I’m STILL a “beware or the cautious man” whose focus has always been “warning analysis” … earnings’ season is NOT over … my advice, trim and skim any new highs if one can!”

RMi’s daily report is a primer that may say little or a lot; yet it serves as insurance that all indications are being examined and evaluated.

WHY do I keep analyzing Biostage (BSTG): When one sees an inextricable wrong and morally repulsive scenario; it takes courage, resolve and patience to stay the course of asking the questions without response!

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice. Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.